Comparative Effectiveness of Chinese Patent Medicines for Chronic Prostatitis/Chronic Pelvic Pain Syndrome: A Bayesian Network Meta-Analysis
Journal of Pain Research · 2026-01 · Volume 19 · 1-11
DOI: 10.2147/jpr.s560430 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Pain Research, 2026-01. Verfasst von Shuai Lin und 4 weiteren Autor:innen. Beteiligte Einrichtung: Zhongshan Hospital of Traditional Chinese Medicine Affiliated to Guangzhou University of Traditional Chinese Medicine, Zhongshan, Guangdong, People's…. Die Arbeit nennt 101 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
Objective
Chronic Prostatitis/Chronic Pelvic Pain Syndrome (CP/CPPS) presents with persistent pelvic pain, urinary symptoms, and psychological burden, severely affecting patients' quality of life. While antibiotics and α-blockers are commonly prescribed, their long-term efficacy is limited and adverse reactions are frequent. Chinese patent medicines (CPMs) have emerged as promising alternatives, yet the lack of head-to-head evidence among formulations hinders evidence-based clinical recommendations.
Methods
Eight databases-CNKI, WanFang, VIP, SinoMed, PubMed, Web of Science, Embase, and the Cochrane Library-were searched from inception to November 1, 2025. Randomized controlled trials enrolling adults with CP/CPPS treated with CPMs versus standard therapy (ST) were included. Bias was assessed with ROB 2, and evidence certainty with CINeMA. A Bayesian network meta-analysis was performed, and outcomes were summarized using forest plots, league tables, and SUCRA curves in RStudio.
Results
Seventy-six trials (n=8431) involving 12 CPMs were analyzed. All studies were conducted in China, and all CPMs outperformed ST in enhancing the total effective rate and reducing NIH-CPSI scores. Shuangshi Tonglin Capsules (SSTL) ranked highest for both overall efficacy (OR = 5.6; 95% CI [2.0, 17]; SUCRA 73.8%) and NIH-CPSI reduction (MD = -8.0; 95% CI [-11, -4.8]; SUCRA 93.3%). SSTL also provided the largest improvements in pain (MD = -5.4; 95% CI [-8.0, -2.8]) and quality of life (MD = -4.3; 95% CI [-5.7, -2.9]).
Conclusion
Compared with ST, CPMs significantly improved CP/CPPS symptoms, with SSTL showing the greatest overall benefit. However, since all included studies originated from China, the generalizability of these findings to other populations may be limited.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Zhongshan Hospital of Traditional Chinese Medicine Affiliated to Guangzhou University of Traditional Chinese Medicine, Zhongshan, Guangdong, People's Republic of China.
- Zhongshan Hospital of Traditional Chinese Medicine, Zhongshan, Guangdong, People's Republic of China.
- Shenzhen Traditional Chinese Medicine Hospital, Shenzhen, Guangdong, People's Republic of China.
Zitieren
APA
Lin, S., Huang, W., Liu, R., Xu, J., & Li, Y. (2026). Comparative Effectiveness of Chinese Patent Medicines for Chronic Prostatitis/Chronic Pelvic Pain Syndrome: A Bayesian Network Meta-Analysis. Journal of Pain Research, Volume 19, 1-11. https://doi.org/10.2147/jpr.s560430
Vancouver
Lin S, Huang W, Liu R, Xu J, Li Y. Comparative Effectiveness of Chinese Patent Medicines for Chronic Prostatitis/Chronic Pelvic Pain Syndrome: A Bayesian Network Meta-Analysis. Journal of Pain Research. 2026;Volume 19:1-11. doi:10.2147/jpr.s560430
BibTeX
@article{Lin2026,
author = {Lin, Shuai and Huang, Wenrui and Liu, Ruxin and Xu, Juan and Li, Yanlin},
title = {Comparative Effectiveness of Chinese Patent Medicines for Chronic Prostatitis/Chronic Pelvic Pain Syndrome: A Bayesian Network Meta-Analysis},
journal = {Journal of Pain Research},
year = {2026},
volume = {Volume 19},
pages = {1--11},
doi = {10.2147/jpr.s560430}
}
EUVIMED